18F‐FDG‐PET/CT imaging in diagnostic workup of pediatric precursor B‐cell lymphoblastic lymphoma

18F‐fluorodeoxyglucose‐positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B‐cell precursor lymphoblastic lymphoma (BCP‐LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold st...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2023-11, Vol.70 (11)
Main Authors: Kroeze, Emma, Laura Arias Padilla, Burkhardt, Birgit, Attarbaschi, Andishe, Hannah von Mersi, Rejin Kebudi, Nievelstein, Rutger A J, Tolboom, Nelleke, Hagleitner, Melanie M, Kuiper, Roland P, Beishuizen, Auke, Loeffen, Jan L C
Format: Article
Language:English
Subjects:
Computed tomography
Hematology
Lymph nodes
Lymphoma
Oncology
Pediatrics
Positron emission tomography
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:18F‐fluorodeoxyglucose‐positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B‐cell precursor lymphoblastic lymphoma (BCP‐LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP‐LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol‐based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.30642